Biomarker Research for Personalized Medicine
1 other identifier
observational
1,000
1 country
1
Brief Summary
The aim of this study :
- 1.Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
- 2.Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 6, 2011
CompletedFirst Posted
Study publicly available on registry
December 8, 2011
CompletedMay 31, 2013
May 1, 2013
December 6, 2011
May 30, 2013
Conditions
Eligibility Criteria
healthy volunteers
You may qualify if:
- Korean
- Clinical diagnosis of Hematologic neoplasms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Inje Universitylead
Study Sites (1)
Inje University
Busan, 614-735, South Korea
Biospecimen
whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Pharmacology and Pharmacogenomics Research Center
Study Record Dates
First Submitted
December 6, 2011
First Posted
December 8, 2011
Study Start
April 1, 2009
Last Updated
May 31, 2013
Record last verified: 2013-05